Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Agusti, W. De Backer, L. de Teresa, M. Zvarich, N. Locantore, N. Barnes, J. Bourbeau, C. Crim (Alicante, Spain; Wilrijk, Belgium; Research Triangle Park, United States Of America; London, United Kingdom; Montreal, Canada). Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD. Eur Respir J 2012; 40: Suppl. 56, 2889

Member's Comments

No comment yet.

Related content which might interest you: Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone Source: International Congress 2017 – Asthma management Year: 2017 Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 The safety of double dose salmeterol/fluticasone proprionate (SFC) in adult asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i.diskus) as first-line regular asthma treatment Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003 Response to therapy with fluticasone propionate/salmeterol 250/50 or ipratropium/albuterol in population subgroups of patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD Source: Eur Respir J 2014; 43: 763-772 Year: 2014 Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002 Dynamics of lung function in children treated with salmeterol/ fluticasone propionate combination (SFC) Source: Eur Respir J 2003; 22: Suppl. 45, 497s Year: 2003 Superiority of the ‘triple‘ therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007 Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON) Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003 Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015